Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;70 Suppl 6(Suppl 6):e30580.
doi: 10.1002/pbc.30580. Epub 2023 Jul 28.

Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Sharon M Castellino  1 , Lisa Giulino-Roth  2 , Paul Harker-Murray  3 , Justine M Kahn  4 , Christopher Forlenza  5 , Steve Cho  6 , Bradford Hoppe  7 , Susan K Parsons  8 , Kara M Kelly  9 ; COG Hodgkin Lymphoma Committee  1
Affiliations

Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Sharon M Castellino et al. Pediatr Blood Cancer. 2023 Sep.

Abstract

The goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials include: (i) superior event-free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high-risk disease, (ii) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and (ii) the potential to select a population that can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead a National cancer Institute National Clinical Trials Network phase 3 trial to evaluate the combination of Bv/nivolumab in early-stage disease. Ongoing advances in technology and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.

Trial registration: ClinicalTrials.gov NCT00302003 NCT00025259 NCT01026220 NCT00107198 NCT00433459 NCT02166463 NCT03407144 NCT03907488 NCT01920932 NCT05705531 NCT05675410 NCT01896999.

Keywords: AYA; Hodgkin lymphoma; pediatric.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prognostic Factors. Blood, Tissue and Imaging Biomarkers toward advancing therapy in Pediatric Hodgkin Lymphoma
See this image and copyright information in PMC

References

    1. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. Feb 10 2011;117(6):1806–16. doi: 10.1182/blood-2010-04-278796 - DOI - PMC - PubMed
    1. Oeffinger KC, Stratton KL, Hudson MM, et al. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. Jul 10 2021;39(20):2266–2275. doi: 10.1200/JCO.20.01186 - DOI - PMC - PubMed
    1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999–2019): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2022. https://gis.cdc.gov/Cancer/USCS/#/Demographics/(accessed July 29, 2022). Accessed may 30, 2023,
    1. Kahn JM, Pei Q, Friedman DL, et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials. The Lancet Haematology. 2022;9(1):e49–e57. doi: 10.1016/S2352-3026(21)00349-5 - DOI - PMC - PubMed
    1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. Nov 1989;7(11):1630–6. doi: 10.1200/jco.1989.7.11.1630 - DOI - PubMed

Associated data